Multi-Institutional Patterns of Use of Tumor-Treating Fields for Patients with Malignant Pleural Mesothelioma

Tugce Kutuk, Department of Radiation Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL 33176, USA.
Joshua M. Walker, Department of Radiation Medicine, Oregon Health & Science University, Portland, OR 97239, USA.
Matthew T. Ballo, Department of Radiation Oncology, West Cancer Center & Research Institute, Memphis, TN 38138, USA.
Robert B. Cameron, Department of Thoracic Surgery, UCLA Health, Los Angeles, CA 90095, USA.
Jean Bustamante Alvarez, Department of Thoracic Oncology, West Virginia University Healthcare, Morgantown, WV 26506, USA.
Sheema Chawla, Rochester Regional HealthFollow
Eric Luk, Department of Medical Oncology, Ochsner Benson Cancer Center, Jefferson, LA 70121, USA.
Deepti Behl, Department of Medical Oncology, Sutter Health-Sutter Cancer Center, Sacramento, CA 95816, USA.
Alan Dal Pra, Department of Radiation Oncology, University of Miami Miller School of Medicine, Miami, FL 33125, USA.
Neil Morganstein, Department of Medical Oncology, Atlantic Health System, Morristown, NJ 07960, USA.
Tamer Refaat, Department of Radiation Oncology, Stritch School of Medicine, Loyola University Chicago, Loyola University Medical Center, Maywood, IL 60153, USA.
Arshin Sheybani, Department of Radiation Oncology, John Stoddard Cancer Center, Des Moines, IA 50309, USA.
Christian Squillante, Department of Medical Oncology, Virginia Piper Cancer Institute, Minneapolis, MN 55404, USA.
Jun Zhang, Division of Medical Oncology, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS 64154, USA.
Rupesh Kotecha, Department of Radiation Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL, USA.

Department

Radiation Oncology

Document Type

Article

Publication Title

Current Oncology (Toronto, Ont.)

Abstract

(1) Background: The objective of this analysis was to evaluate the device usage rates and patterns of use regarding Tumor-Treating Fields (TTFields) for patients with malignant pleural mesothelioma (MPM) throughout the US.

(2) Methods: We evaluated de-identified data from 33 patients with MPM enrolled in FDA-required HDE protocols at 14 institutions across the US from September 2019 to March 2022.

(3) Results: The median number of total TTFields usage days was 72 (range: 6-649 days), and the total treatment duration was 160 months for all patients. A low usage rate (defined as less than 6 h per day, 25%) was observed in 34 (21.2%) months. The median TTFields usage in the first 3 months was 12 h per day (range: 1.9-21.6 h), representing 50% (range: 8-90%) of the potential daily duration. The median TTFields usage after 3 months decreased to 9.1 h per day (range: 3.1-17 h), representing 38% (range: 13-71%) of the daily duration, and was lower than usage in the first 3 months (p = 0.01).

(4) Conclusions: This study represents the first multicenter analysis of real-world TTFields usage based on usage patterns for MPM patients in clinical practice. The real-world usage level was lower than the suggested daily usage. Further initiatives and guidelines should be developed to evaluate the impact of this finding on tumor control.

First Page

5195

Last Page

5200

DOI

10.3390/curroncol30060394

Volume

30

Issue

6

Publication Date

5-23-2023

Medical Subject Headings

Humans; Mesothelioma, Malignant; Neoplasms

PubMed ID

37366877

Link to Full Text

Share

COinS